CELC — Celcuity Inc.
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1603454 ·
Last close
$58.01
Market Cap
$2.84B
52W High
$151.02
52W Low
$53.54
ADV30
1,542,085
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -77,319,000 | -73,337,000 | 726,869,000 | 178,165,000 | 800,908,000 |
| Jun 2026 | 0 | — | -66,118,000 | -78,864,000 | 828,220,000 | 182,049,000 | 841,001,000 |
| Mar 2026 | 0 | — | -50,507,000 | -52,841,000 | 410,164,000 | 145,191,000 | 356,639,000 |
| Dec 2025 | 0 | — | -49,201,000 | -50,973,000 | 466,558,000 | 165,703,000 | 366,003,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-191,706,000
Investing CF
$-450,273,000
Financing CF
$777,674,000
CapEx
$-571,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.30
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-580,602,000
Inventory
—
Receivables
—
ST Investments
$571,995,000
EBIT TTM
$-204,213,000
Pretax Income TTM
$-226,482,000
Interest Exp TTM
$22,269,000
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -172,192,000 | -177,042,000 | 466,558,000 | 366,003,000 | 100,555,000 | -153,280,000 |
| Dec 2024 | 0 | -113,267,000 | -111,779,000 | 245,123,000 | 129,504,000 | 115,619,000 | -83,467,000 |
| Dec 2023 | 0 | -66,230,331 | -63,779,116 | 191,219,398 | 51,450,076 | 139,769,322 | -53,812,253 |
| Dec 2022 | 0 | -39,391,091 | -40,370,040 | 175,697,097 | 41,925,630 | 133,771,467 | -36,008,171 |
TTM Snapshot
Revenues TTM
$15,939,000
NetIncome TTM
$-226,482,000
OpCashFlow TTM
—
Assets (Latest)
$828,220,000
Forward EPS
$0.57
Max Pain — expiry 2027-01-15
max pain strike: $60.00 · spot: $55.60 · call oi: 7,343 · put oi: 2,225
Expected Move to 2027-01-15:
±$13.45
(24.19%) —
implied range
$42.15 –
$69.05
· ATM straddle on $55.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PGNY | Progyny, Inc. | $2.70B | $36.71 | — |
| AVAH | Aveanna Healthcare Holdings, Inc. | $2.54B | $11.65 | — |
| PRVA | Privia Health Group, Inc. | $3.19B | $24.99 | — |
| ARDT | Ardent Health, Inc. | $2.50B | $17.75 | — |
| NHC | NATIONAL HEALTHCARE CORP | $3.22B | $205.77 | — |
News headlines (Yahoo Finance, 1h cache)
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
2026-11-09 13:30 · Yahoo
Celcuity (CELC) Q3 2026 Earnings Call Transcript
2026-11-06 17:05 · Yahoo
Celcuity Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
Celcuity Inc (CELC) Q3 2026 Earnings Call Highlights: Revtorpic's Strong Launch Momentum Meets ...
2026-11-06 07:22 · Yahoo
What Celcuity (CELC) Said on Its Q3 Earnings Call
2026-11-06 03:14 · Yahoo
Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 21:01 · Yahoo
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
2026-10-29 12:30 · Yahoo
Will Breast And Prostate Cancer Data Change Celcuity (CELC) Narrative
2026-10-25 20:10 · Yahoo
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
2026-10-24 08:15 · Yahoo
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
2026-10-23 13:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.